Impact of emerging ACA on survival in chronic myeloid leukemia (CML)

Detalles Bibliográficos
Autores principales: Hehlmann, Rüdiger, Lauseker, Michael, Voskanyan, Astghik, Fabarius, Alice, Haferlach, Claudia, Hochhaus, Andreas, Saußele, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522580/
https://www.ncbi.nlm.nih.gov/pubmed/35999258
http://dx.doi.org/10.1038/s41375-022-01681-3
_version_ 1784800094013358080
author Hehlmann, Rüdiger
Lauseker, Michael
Voskanyan, Astghik
Fabarius, Alice
Haferlach, Claudia
Hochhaus, Andreas
Saußele, Susanne
author_facet Hehlmann, Rüdiger
Lauseker, Michael
Voskanyan, Astghik
Fabarius, Alice
Haferlach, Claudia
Hochhaus, Andreas
Saußele, Susanne
author_sort Hehlmann, Rüdiger
collection PubMed
description
format Online
Article
Text
id pubmed-9522580
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95225802022-10-01 Impact of emerging ACA on survival in chronic myeloid leukemia (CML) Hehlmann, Rüdiger Lauseker, Michael Voskanyan, Astghik Fabarius, Alice Haferlach, Claudia Hochhaus, Andreas Saußele, Susanne Leukemia Correspondence Nature Publishing Group UK 2022-08-23 2022 /pmc/articles/PMC9522580/ /pubmed/35999258 http://dx.doi.org/10.1038/s41375-022-01681-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Correspondence
Hehlmann, Rüdiger
Lauseker, Michael
Voskanyan, Astghik
Fabarius, Alice
Haferlach, Claudia
Hochhaus, Andreas
Saußele, Susanne
Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
title Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
title_full Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
title_fullStr Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
title_full_unstemmed Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
title_short Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
title_sort impact of emerging aca on survival in chronic myeloid leukemia (cml)
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9522580/
https://www.ncbi.nlm.nih.gov/pubmed/35999258
http://dx.doi.org/10.1038/s41375-022-01681-3
work_keys_str_mv AT hehlmannrudiger impactofemergingacaonsurvivalinchronicmyeloidleukemiacml
AT lausekermichael impactofemergingacaonsurvivalinchronicmyeloidleukemiacml
AT voskanyanastghik impactofemergingacaonsurvivalinchronicmyeloidleukemiacml
AT fabariusalice impactofemergingacaonsurvivalinchronicmyeloidleukemiacml
AT haferlachclaudia impactofemergingacaonsurvivalinchronicmyeloidleukemiacml
AT hochhausandreas impactofemergingacaonsurvivalinchronicmyeloidleukemiacml
AT saußelesusanne impactofemergingacaonsurvivalinchronicmyeloidleukemiacml

Ejemplares similares